Life-years lost associated with mental illness: a cohort study of beneficiaries of a South African medical insurance scheme

Yann Ruffieux*¹, Anja Wettstein*¹, Gary Maartens², Naomi Folb³, Cristina Mesa Vieira^{1,4}, Christiane Didden^{1,5}, Mpho Tlali⁶, Chanwyn Williams³, Morna Cornell⁶, Michael Schomaker⁷, Leigh F Johnson⁶, John A Joska^{8,9}, Matthias Egger^{1,6,10}, Andreas D Haas¹

*Joint first authors

- 1 Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
- 2 Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
- 3 Medscheme, Cape Town, South Africa
- 4 Graduate School of Health Sciences, University of Bern, Bern, Switzerland
- 5 Institute of Sociology, Ludwig-Maximilians-University, Munich, Germany
- 6 Centre for Infectious Disease Epidemiology & Research, School of Public Health, University of Cape Town, Cape Town, South Africa
- 7 Department of Statistics, Ludwig-Maximilans-Universität München, Germany
- 8 HIV Mental Health Research Unit, Neuroscience Institute, University of Cape Town, Cape Town, South Africa
- 9 Division of Neuropsychiatry, Department of Psychiatry and Mental Health, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
- 10 Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK

Corresponding author:

Andreas D. Haas Mittelstrasse 43 3012 Bern, Switzerland Phone: +41 31 684 35 23

Email: andeas.haas@ispm.unibe.ch

Summary

Background

People with mental illness have a reduced life expectancy, but the extent of the mortality gap and the contribution of natural and unnatural causes to excess mortality among people with mental illness in South Africa are unknown.

Methods

We analysed reimbursement claims and vital registration data from South African medical insurance scheme beneficiaries aged 15–85 years. We estimated excess life years lost (LYL) associated with organic, substance use, psychotic, mood, anxiety, eating, personality, developmental or any mental disorders.

Findings

We followed 1 070 183 beneficiaries, of whom 282 926 (26·4%) received mental health diagnoses. Life expectancy of people with mental health diagnoses was 3·83 years (95% Cl 3·58–4·10) shorter for men and 2·19 years (1·97–2·41) shorter for women. Excess mortality varied by sex and diagnosis, ranging from 11·50 LYL (95% Cl 9·79–13·07) among men with alcohol use disorder to 0·87 LYL (0·40–1·43) among women with generalised anxiety disorder. Most LYL were attributable to natural causes (3·42 among men and 1·94 among women). A considerable number of LYL were attributable to unnatural causes among men with bipolar (1·52) or substance use (2·45) disorder.

Interpretation

The burden of premature mortality among persons with mental disorders in South Africa is high. Our findings support implementing interventions for prevention, early detection, and treatment of physical comorbidities among people with mental disorders. Suicide prevention and substance use treatment programmes are needed to reduce excess mortality from unnatural causes, especially among men.

Funding

Swiss National Science Foundation and National Institutes of Health

Research in Context

Evidence before this study

We searched PubMed with no language restriction from inception until April 12, 2022, for studies from sub-Saharan African countries on excess mortality among people with mental illness. We used the search string "mental disorders/mortality" as a major MeSH term and a filter for African countries. We identified four relevant studies: three from Ethiopia and one from South Africa. In Ethiopia, mortality in people with schizophrenia was six times higher than in the general population (standardised mortality ratio [SMR] 5.98; 95% confidence interval (CI) 4.09–7.87) and three to four times higher in those with major depression (SMR 3.55; 95% CI 1.97–6.39). Another study from Ethiopia found that people with severe mental disorders, including schizophrenia, bipolar disorder, and severe depression, died 28 years earlier than the general population. Most patients with severe mental disorders died from infectious diseases, suicides, or traffic accidents. Among people living with HIV in South Africa, those diagnosed with or treated for mental illness had a three times higher mortality risk (adjusted hazard ratio 2.98, 95% CI 2.69–3.30) than those without diagnoses or not treated for mental health conditions.

Added value of our study

This study is one of Africa's most comprehensive analyses of excess mortality among people with mental illness. We compared mortality rates between 280,000 medical insurance beneficiaries receiving mental health diagnoses in primary, secondary and tertiary care, and 785,000 without mental health diagnoses. In contrast to earlier studies —conducted mainly among people with severe mental illness—our study included a broader sample of people with a spectrum of mental disorders, including common mental disorders. We found life expectancy of people with mental health diagnoses was about 4 years shorter for men and about 2 years shorter for women compared with beneficiaries of the same age and sex without mental health diagnoses. Eating, developmental, psychotic, substance use, and organic mental disorders were associated with high excess mortality, especially among men and people diagnosed in hospitals. In contrast, women diagnosed with anxiety or depression had lower excess mortality. Most LYL associated with mental disorders were attributable to death by natural causes. Among men with alcohol use, drug use, or bipolar disorders, death by unnatural causes accounted for a considerable excess mortality burden.

Implications of available evidence

Our study demonstrates a considerable burden of premature death from natural causes among a relatively small group of people with certain mental disorders. Our findings support recommendations to implement interventions for prevention, early detection, and appropriate treatment of physical comorbidities among people with these disorders. To reduce excess mortality from unnatural causes among men with bipolar and substance use disorders, we recommend suicide prevention and substance use treatment programmes.

Introduction

Mental illness is a leading and increasing cause of disease burden globally. In South Africa, the total number of disability-adjusted life years attributable to mental illness nearly doubled from 550 000 to 929 000 over the past 30 years. Mental disorders now rank among the top ten leading causes of disease burden in South Africa, with a lifetime prevalence of mental disorders in South Africa estimated at 30%.

Although most mental disorders do not lead directly to death, they increase the risk of suicide, accidental death, and premature mortality from physical illness.^{3–6} Higher rates of premature mortality from physical illness can be attributed to a higher incidence of physical comorbidities among people with mental illness and worse access to or engagement in health care.^{4,7} Physical illnesses can also increase the risk of mental illness due to various biological and psycho-social mechanisms.⁸

Meta-analyses of studies—mainly from high-income countries—demonstrated that people with mental illnesses, particularly those with severe conditions, have more than double the mortality rates of the general population and die on average 10 years prematurely.^{5,9} Due to differences in life expectancy and disease burden, estimates from high-income countries cannot be generalised to low- and middle-income settings. However, evidence from low- and middle-income settings^{5,9} is scarce.^{10–12}

We aimed to investigate excess mortality among people with mental illness in South Africa. We analysed longitudinal reimbursement claims and vital registration data of beneficiaries of a large South African medical insurance scheme. We calculated excess life years lost (LYL) and adjusted hazard ratios (HRs) for excess mortality among people diagnosed with a mental illness.

Methods

Study design and participants

We analysed longitudinal reimbursement claims and vital registration data of a cohort of beneficiaries of a large South African medical insurance scheme. Reimbursement claims contained International Classification of Diseases, tenth revision (ICD-10) diagnoses made in outpatient and hospital settings. Eligible beneficiaries for our analysis were aged 15–84 years and covered by medical insurance at any point between January 1, 2011, and June 30, 2020. We excluded people of unknown age and sex and those whose vital status could not be ascertained based on the linkage to the National Population Register (NPR) (appendix, <u>figure S1</u>). The Human Research Ethics Committee of the University of Cape Town and the Cantonal Ethics Committee of the Canton of Bern granted permission to analyse these data.

Procedures

Our primary exposures were ICD-10 diagnoses of mental disorders made in outpatient or hospital settings. We grouped diagnoses into organic mental disorders (ICD-10 codes F00-F09), substance use disorders (F10–F17, F19), psychotic disorders (F20–F29), mood disorders (F30–F39), anxiety disorders (F40–F48), eating disorders (F50), personality disorders (F60–F69), developmental disorders (F80–F89), or any mental disorder (F00–F99). We further subdivided substance use disorders into alcohol use disorder (F10) and drug use disorders (F11–F17, F19), mood disorders into bipolar disorders (F31) and depressive disorders (F32–F33, F34.1), and anxiety disorders into generalised anxiety disorder (F41.1) and post-traumatic stress disorder (F43.1).

In secondary analyses, we only analysed ICD-10 diagnoses made in a hospital setting and psychiatric medication prescriptions as proxies for mental disorders. We grouped psychiatric medication following the World Health Organization's Anatomical Therapeutic Chemical classification system into substance use medication (N07B), antipsychotic (N05A), antidepressant (N06A), anxiolytic (N05B), or any psychiatric medication (N05A, N05B, N06A, and N07B).

We ascertained the vital status of beneficiaries based on mortality records from NPR and the medical insurance database. If the death dates recorded by the medical insurance did not match NPR data, we used death dates from NPR. Finally, we divided mortality by natural, unnatural, or unknown causes of death. Unnatural causes include all deaths by external causes, such as suicides, homicides, accidents, medical errors, alcohol intoxications and drug overdoses (ICD10 V01—Y98) and natural causes include all causes of death from chapters 1 to 18 of the ICD-10.¹³ Unknown causes include death under investigation at the time of linkage, death due to unidentified causes, and death recorded only by the medical insurance but not by the NPR.

Statistical analysis

For each individual, we defined baseline as either the date of enrolment in the medical insurance scheme, their 15th birthday, or January 1, 2011, whichever occurred later. We followed people from baseline to the end of insurance coverage, death, their 85th birthday, or June 30, 2020, whichever occurred first. We assessed the distribution of sex, baseline age, and baseline calendar year for participants with and without mental health diagnoses.

We estimated LYL of people with mental health diagnoses and psychiatric medication. LYL measures the average difference in life expectancy among people with mental health diagnoses between the dates of diagnoses and their 85th birthday, compared to people of the same age and sex without mental health diagnoses. Individuals were considered unexposed until receiving a first mental health diagnosis and exposed from the date of their first diagnosis of the mental illness of interest. Using a competing risks model, we disaggregated LYL by cause of death (natural, unnatural, or unknown). We produced 95% CI for the LYL estimates using bootstrap simulation. Most mental health diagnoses were recorded multiple times because ICD-10 codes are submitted with each outpatient and hospital claim. In sensitivity analyses, we restricted analysis of LYL to persons with a single ICD-10 diagnosis of a mental disorder that could result from a coding error. In another sensitivity analysis, we did not censor follow-up at the end of insurance coverage if the person died within 1 year of the end of insurance coverage to account for deaths occurring after losing insurance coverage.

Using multivariable Cox proportional hazard models, we estimated HRs with 95% CIs for associations between each exposure and mortality from all causes, natural causes, and unnatural causes. All Cox models were adjusted for the exposure of interest (time-updated variable with the individual switching from unexposed to exposed at the time of the first diagnosis of the mental illness of interest), baseline age (categories 15-24, 25-39, 40-54, 55-74, 75-84), and calendar period (time-updated by categories January 1, 2011–December 31, 2013; January 1, 2014–December 31, 2016; January 1, 2017–March 14, 2020; March 15-June 30, 2020). We chose the March 15, 2020, cut-off for the calendar period to coincide with the beginning of the COVID-19 pandemic in South Africa. We fitted separate models adjusting and not adjusting for psychiatric comorbidity. Models adjusted for psychiatric comorbidity included binary indicators for organic mental disorders, substance use disorders, psychotic disorders, mood disorders, anxiety disorders, behavioural syndromes associated with physiological disturbances and physical factors (F50-F59), personality disorders, developmental disorders and behavioural disorders (F90-F98). In addition, we tested for interactions between sex and each exposure. We estimated HRs separately for each sex and with both sexes combined while adjusting for sex. We tested the proportional hazards assumption using a test based on Schoenfeld residuals and visual inspection of log-log plot of the survivor functions. Because the proportional hazards assumption was violated for several exposures, we performed additional analyses where we split analysis time at one- and two-year marks after the start of their time-at-risk and produced an adjusted HR for each interval.

We performed statistical analyses using R 4.1.2 (R Foundation for Statistical Computing, Vienna, Austria) and Stata (Version 16. College Station, TX: StataCorp). We used the R package *lillies* to compute LYL. 17

Role of funding sources

Study funders had no role in study design; data collection, analysis, or interpretation; or writing the manuscript.

Results

We followed 1 070 183 people (517 305 men and 552 878 women) for a median duration of 3·0 years [interquartile range (IQR) $1\cdot2-6\cdot1$) (appendix, Figure S1). The characteristics of people with and without mental health diagnoses are shown in Table 1.

During follow-up, 282 926 beneficiaries (26·4%) received a mental health diagnosis (<u>Table 2</u>). The proportion of beneficiaries who received mental health diagnoses was higher among women (30·5%) than men (22·1%). The most common mental health diagnoses were anxiety disorders (16·6%), including generalised anxiety disorder (3.0%) post-traumatic stress disorder (1·3%) and mood disorders (14·6%), including depressive disorders (14·1%) and bipolar disorder (1·8%). The proportion of beneficiaries diagnosed with organic, substance use, psychotic, eating, developmental, and personality disorders was below 1% (<u>Table 2</u>). Psychiatric comorbidity was common. For example, among beneficiaries diagnosed with a psychotic disorder, 75·2% had also been diagnosed with a mood disorder (appendix, <u>Figure S2</u>). A total of 45 579 beneficiaries (4·3%) received a mental health diagnosis in a hospital (appendix, <u>Table S1</u>). Over one-third of the study population was prescribed a psychiatric medication (34·8%), including antidepressant (22·3%), anxiolytic (22·1%), antipsychotic (9·5%), and substance use (0·5%) medication (appendix, <u>Table S2</u>).

Figure 1 shows LYL among men and women who received mental health diagnoses in any health care setting (left panel) or hospital (right panel) compared to beneficiaries of the same sex and age without mental health diagnoses. Men had higher LYL than women for all types of mental illnesses except developmental disorders. For beneficiaries diagnosed in any health care setting (outpatient or hospital), life expectancy after diagnosis of any mental disorder was 3·83 years (95% Cl 3·58–4·10) shorter for men and 2·19 years (1·97–2·41) shorter for women when compared to beneficiaries of the same age and sex without mental health diagnoses. The life expectancy of men diagnosed with an organic mental disorder, alcohol use disorder, drug use disorder, or psychotic disorder was reduced by over 10 years. Women with organic or alcohol use disorder had a similar mortality gap of 10 years. Psychotic and drug use disorders among women and developmental and eating disorders for both sexes were associated with an LYL of 7 to 10 years. Women with common mental disorders showed low excess mortality, for example: 0·87 (95% Cl 0·40–1·43) LYL for generalised anxiety disorder and 2·47 (2·17–2·74) LYL for depressive disorders.

When considering diagnoses from hospital settings only, LYL associated with mental health diagnoses increased to 12·15 years (95% CI 11·59–12·70) among men and 8·67 (95% CI 8·20–9·13) among women (<u>Figure 1</u>, right panel, appendix <u>Table S3</u>). Women hospitalised with an eating disorder (21·17 LYL, 95% CI 16·38–25·18) and men hospitalised with a psychotic disorder (15·29 LYL, 95% CI 12·79–17·61) showed the largest mortality gap.

Most LYL were attributable to natural causes (<u>Tables 3</u>): in men, 3.42 (95% Cl 3.17-3.70) LYL associated with any mental health diagnosis were from natural causes, 0.45 (95% Cl 0.32-0.59) from unnatural causes, and -0.04 (95% Cl -0.11-0.03) from unknown causes; in women, 1.94 (95% Cl 1.73-2.15) LYL were from natural causes, 0.22 (95% Cl 0.15-0.28) were from unnatural causes, and 0.03 (95% Cl -0.02-0.09) were from unknown causes. Among men, a considerable excess mortality burden was attributable to unnatural causes with alcohol use disorders (LYL 2.49, 95% Cl 1.41-3.60), drug use disorders (LYL 2.05, 95% Cl 0.58-3.77), and bipolar disorders (LYL 1.52, 95% Cl 0.90-2.17). Among women with drug use disorder 1.85 (95% Cl 0.34-3.69) LYL were attributable to unnatural causes.

Use of psychiatric medication was associated with 4.05 LYL (95% CI 3.79-4.12) among men and 2.26 LYL (95% CI 2.05-2.48) among women (appendix, <u>Table S4</u>). When limiting exposures to beneficiaries with only one mental health diagnosis, LYL increased to 5.61 years (95% CI 5.17-6.10) among men and 4.41 (95% CI 3.96-4.84) among women (appendix, <u>Table S5</u>). Including deaths occurring within 1 year after an individual's insurance plan ended did not markedly change results (appendix, <u>Table S6</u>).

Figure 2 shows adjusted HR comparing all-cause mortality of people with and without organic, substance use, psychotic, mood, anxiety, developmental, personality or any mental disorder. The mortality rate was 65% higher among people diagnosed with mental disorders than those without mental health diagnoses (HR 1 65, 95% CI 1 61–1 69). In models adjusted for age, sex, and calendar year (model 1), the greatest increase in mortality risk was among people diagnosed with organic mental disorders (HR 6.01 [95% CI 5.74-6.29]), followed by those diagnosed with psychotic (3.12 [2.83-3.43]), substance use (2.93 [2.64–3.25]), developmental (1.67 [1.31–2.12]), personality (1.65 [1.27–2.15]), mood (1.59 [1.55–1.65]), and anxiety (1.24 [1.20–1.27]) disorders. After further adjusting for psychiatric comorbidity (model 2), associations were attenuated. For example, the HR for psychotic disorders decreased to 148 (95% CI 134-164) and anxiety disorders were no longer associated with all-cause mortality (HR 1.03, 95% CI 0.99-1.06). Excess mortality associated with any mental health diagnosis decreased with follow-up time: from an adjusted HR of 1.96 (95% CI 1.82-2.10) in year 1 of follow-up to an adjusted HR of 1.60 (95% CI 1.56–1.65) beyond the second year of follow-up (appendix, Table S7). Mental health diagnoses of most types were associated with a higher risk of natural and unnatural deaths (appendix, Table S8). Mental health diagnoses during hospitalisations were associated with a 279% increase in mortality risk (HR 3·79, 95% Cl 3·66–3·93) (appendix, Table S9). Psychiatric medications were associated with a 77% increase in mortality risk (HR 1·77, 95% CI 1·73–1·81) (appendix, Table S10).

Discussion

In this cohort of South African medical insurance beneficiaries, 22% of men and 31% of women received mental health diagnoses. On average, the remaining life expectancy after a mental health diagnosis was 3.8 years shorter for men and 2.2 years shorter for women compared to people without mental health diagnoses. The difference in life expectancy varied by sex and disorder. Eating disorders, developmental disorders, psychotic disorders, substance use disorders, and organic mental disorders were strongly associated with LYL, especially among men. In contrast, women with anxiety or depression had lower excess mortality. Most excess deaths among people with mental illness were attributable to natural causes.

To our knowledge, this study presents the most comprehensive analysis of excess mortality among people with mental illness in Africa. We compared mortality between 280,000 people with and 785,000 people without mental health diagnoses. Earlier studies of excess mortality mainly included people with severe mental illness managed in tertiary care hospitals. Our study included people with a broad spectrum of disorders managed at all levels of care. We ascertained mortality by linking data from a medical insurance scheme to the South African civil registration system. According to a validation study, the mortality linkage should have identified about 95% of adult deaths. The mortality data included cause of death information, allowing us to disaggregate excess mortality estimates into deaths attributable to natural and unnatural causes. Finally, we used international diagnostic criteria for the full spectrum of mental disorders to evaluate excess mortality among people with various mental health conditions while adjusting for psychiatric comorbidity.

Although the Global Burden of Disease (GBD) study recognises mental disorders as leading causes of disease burden, it likely underestimates their true burden. Most mental disorders do not directly lead to death but increase the risk of suicide, accidents, and physical illness, indirectly contributing to premature mortality. In the GBD framework, mortality indirectly attributable to mental disorders is attributed to the cause directly leading to death as recorded on death certificates. For example, suicide resulting from depression will be coded as injury and no mortality burden will be attributed to depression. As a result, the GBD's disease burden estimates may not reflect the mortality attributable to mental disorders and hence underestimate the true burden of mental disorders.

We calculated an alternative metric, LYL, to quantify excess mortality among people with mental illness. LYL is a descriptive measure of excess mortality reflecting the direct and indirect causal contributions of mental disorders to premature mortality, but also the effect of non-causal confounding factors, for example, precarious living conditions or physical comorbidities influencing both the risk of a mental disorder and mortality. The metric quantifies the average difference in life expectancy after diagnoses of health conditions compared with people of the same age and sex without such diagnoses. LYL are useful for identifying vulnerable populations at high risk of premature mortality who might benefit from targeted interventions to reduce excess mortality. However, LYL must not be interpreted as reflecting the causal effect of mental disorders on mortality. Causal inference analyses are needed to quantify the mortality burden attributable to mental disorders.

Although most mental disorders were associated with substantial excess mortality, our estimates were generally lower than those reported in previous studies. A meta-analysis of studies primarily from high-income countries estimated that people diagnosed with a mental disorder died about ten years

prematurely. The overrepresentation of people with severe mental illness in earlier work might partly explain the difference between estimates from earlier studies and our work. Many studies included in the meta-analysis relied on medical records from tertiary care settings, including a large proportion of people with psychotic disorders and other severe mental health conditions associated with a high risk of premature mortality. In contrast, our study included a more representative sample of people with mental illness. We identified most mental health diagnoses based on medical records from outpatient settings. Common mental health conditions such as depression and anxiety disorders accounted for most mental health diagnoses. We included people with psychotic disorders and those hospitalised with mental disorders in our study, but persons with severe mental illness were not overrepresented.

People diagnosed with mental illness were at higher risk of death from natural and unnatural causes. Yet, almost 90% of LYL associated with mental disorders were attributable to death from natural causes. Previous studies support this finding. For instance, a register-based cohort study from Denmark attributed 70% (men) and 80% (women) of excess mortality burden to natural causes, including circulatory, respiratory, and alcohol-related liver disease. A community-based cohort study from rural Ethiopia attributed 75% of deaths among people with severe mental illness to natural causes, mainly due to infectious diseases. Higher rates of physical illnesses among people with mental illness and poorer health care contribute to premature death from natural causes among people with mental illness. Appears recommend interventions for reducing the burden of physical illness among people with mental health conditions to close the mortality gap. Interventions can target lifestyle and behaviours to prevent physical illness or early detection and appropriate treatment of common physical comorbidities through screening or collaborative or integrated mental and physical health care models. Furthermore, interventions aiming to reduce stigma towards mental illness among health care providers should be considered.

For some disorders, unnatural causes of death accounted for considerable excess mortality. For example, among men with alcohol use disorder, drug use disorder, or bipolar disorder, unnatural causes of death accounted for about 20–35% of total LYL. Suicide prevention, substance use treatment, and harm reduction programmes are needed to reduce excess mortality from unnatural causes. 3,23

Men with mental illness had higher excess mortality than women with mental illness. For alcohol and bipolar disorders, sex disparities in excess mortality are at least partly attributable to higher mortality from unnatural causes among men than women. For other disorders, lower health care utilisation rates among men compared with women, ²⁴ arising from the gendered nature of health services creating health care barriers for men, ^{25,26} harmful masculine norms, ²⁷ self-stigmatizing beliefs, ²⁸ or differences in coping strategies ²⁹ may contribute to higher excess mortality for men than women. Further work is needed to design, implement, and evaluate strategies addressing men's physical and mental health care needs.

Our study has several limitations. First, we assessed beneficiaries' mental health status based on ICD-10 diagnoses from reimbursement claims; thus, we missed beneficiaries with undiagnosed mental disorders who may be less severely ill than those diagnosed. Furthermore, mental health diagnoses might be affected by diagnostic or administrative errors, 31 although diagnoses from administrative data generally have a high positive predictive value for research diagnoses. Sensitivity analysis of people with only one, possibly erroneous, mental health diagnosis showed high excess mortality, suggesting this population might constitute people with untreated conditions rather than false positive cases.

Second, we did not consider remissions and may have misclassified the person-time of individuals in remission. This could have led to an underestimation of the excess mortality, particularly for depression or anxiety. Third, although mortality from external causes is reliably recorded in South Africa's vital registration system,³² data on the exact causes of death are limited. This prevented us from disaggregating mortality from unnatural causes into suicides and other causes, and mortality from natural causes into different disease categories. Fourth, our study only included data from a private-sector medical insurance scheme. Thus, our findings do not necessarily apply to people accessing the public health care sector. People using public health services generally have lower socioeconomic status. They may be at higher risk of experiencing poor mental health outcomes than employed and insured people who access private services.³³ In addition, access to mental health care in South Africa's public sector is limited and mental disorders often remain untreated.³⁴

In conclusion, our study demonstrates a considerable burden of premature death among people with mental illness primarily attributable to death from natural causes. People diagnosed with eating, developmental, psychotic, substance use, and organic mental disorders—especially men and those hospitalised with these conditions—are at the highest risk of premature death. These findings support implementing interventions for prevention, early detection, and appropriate treatment of physical comorbidities among people with mental illness. In addition, suicide prevention and substance use treatment programmes are needed to reduce excess mortality from unnatural causes among men with bipolar and substance use disorders.

Authors and contributors

YR and AH conceived the study. ME and AH obtained funding for the study. YR, AW and AH wrote the first draft of the study protocol, which was revised by all authors. YR and AW did the analyses. CW, LJ, MS and CD advised on statistical analyses. AW, YR, and AH wrote the first draft of the paper. All other authors contributed to the interpretation of results and critically revised the manuscript for intellectual content. YR, AW and AH had access to and verified the underlying data reported in the manuscript. All authors have approved the final version of the manuscript for submission for publication. Kristin Marie Bivens, PhD from the Institute of Social and Preventive Medicine at the University of Bern, edited the manuscript.

Data sharing

Data were obtained from the International epidemiology Databases to Evaluate AIDS—Southern Africa (IeDEA-SA). Data cannot be made available online because of legal and ethical restrictions. To request data, readers may contact IeDEA-SA for consideration by filling out the online form available at https://www.iedea-sa.org/contact-us/. Statistical code is available under https://github.com/IeDEA-SA/LYL

Declaration of interest

The authors declare no conflicts of interest.

Ethical considerations

The Human Research Ethics Committee of the University of Cape Town, South Africa and the Cantonal Ethics Committee, Bern, Switzerland, granted ethical permission for the analysis. Beneficiaries of the medical scheme or their guardians consented to the use of their data in research.

Acknowledgements

Research reported in this publication was supported by the Swiss National Science Foundation (grant numbers 193381, and 189498) and the US National Institutes of Health (the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Cancer Institute, the National Institute of Mental Health, the National Institute on Drug Abuse, the National Heart, Lung, and Blood Institute, the National Institute on Alcohol Abuse and Alcoholism, the National Institute of Diabetes and Digestive and Kidney Diseases, and the Fogarty International Center) (grant number U01Al069924). Calculations were performed on UBELIX (http://www.id.unibe.ch/hpc), the high-performance computing cluster at the University of Bern.

References

- GBD 2019 collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Psychiatry* 2022; **9**: 137–50.
- Herman A, Stein D, Seedat S, Heeringa S, Moomal H, Williams D. 12 Month and Lifetime Prevalence of Common Mental Disorders. *South African Medical Journal* 2011; **99**: 339–44.
- Liu NH, Dua T, Saxena S, *et al*. Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas. *World Psychiatry* 2017; **16**: 30–40.
- de Hert M, Correll CU, Bobes J, *et al.* Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. *World Psychiatry* 2013; **10**: 52–77.
- 5 Chesney E, Goodwin GM, Fazel S. Risks of all-cause and suicide mortality in mental disorders: A meta-review. *World Psychiatry* 2014; **13**: 153–60.
- Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. *JAMA Psychiatry* 2015; **72**: 334–41.
- de Hert M, Cohen D, Bobes J, *et al.* Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. *World Psychiatry* 2011; **10**: 138–51.
- 8 Prince M, Patel V, Saxena S, et al. No health without mental health. Lancet 2007; **370**: 859–77.
- 9 Walker ER, McGee RE, Druss BG. Mortality in Mental Disorders and Global Disease Burden Implications: A Systematic Review and Meta-analysis. *JAMA Psychiatry* 2015; **72**: 334–41.
- Teferra S, Shibre T, Fekadu A, *et al.* Five-year mortality in a cohort of people with schizophrenia in Ethiopia. *BMC Psychiatry* 2011; **11**. DOI:10.1186/1471-244X-11-165.
- 11 Mogga S, Prince M, Alem A, et al. Outcome of major depression in Ethiopia: Population-based study. *British Journal of Psychiatry* 2006; **189**: 241–6.
- Haas AD, Ruffieux Y, Heuvel LL Van Den, *et al.* Excess mortality associated with mental illness in people living with HIV in Cape Town, South Africa: a cohort study using linked electronic health records. *Lancet Glob Health* 2020; **8**: e1326–34.
- Statistics South Africa. Republic of South Africa. Mortality and causes of death in South Africa: Findings from death notification. 2017.
- 14 Erlangsen A, Andersen PK, Toender A, Laursen TM, Nordentoft M, Canudas-Romo V. Cause-specific life-years lost in people with mental disorders: a nationwide, register-based cohort study. *Lancet Psychiatry* 2017; **4**: 937–45.
- Andersen PK. Life years lost among patients with a given disease. *Stat Med* 2017; **36**: 3573–82.

- Plana-Ripoll O, Pedersen CB, Agerbo E, *et al.* A comprehensive analysis of mortality-related health metrics associated with mental disorders: a nationwide, register-based cohort study. *The Lancet* 2019; published online Oct. DOI:10.1016/S0140-6736(19)32316-5.
- Plana-Ripoll O, Canudas-Romo V, Weye N, Laursen TM, McGrath JJ, Andersen PK. Lillies: An R package for the estimation of excess life years lost among patients with a given disease or condition. *PLoS One* 2020; **15**: 1–18.
- Andersen PK. Decomposition of number of life years lost according to causes of death. *Stat Med* 2013; **32**: 5278–85.
- 19 Vigo D, Thornicroft G, Atun R. Estimating the true global burden of mental illness. *Lancet Psychiatry* 2016; **3**: 171–8.
- Charlson FJ, Baxter AJ, Dua T, Degenhardt L, Whiteford HA, Vos T. Excess mortality from mental, neurological and substance use disorders in the Global Burden of Disease Study 2010. Epidemiology and psychiatric sciences 2015; **24**: 121–40.
- Fekadu A, Medhin G, Kebede D, *et al.* Excess mortality in severe mental illness: 10-Year population-based cohort study rural Ethiopia. *British Journal of Psychiatry* 2015; **206**: 289–96.
- Carrara BS, Fernandes RHH, Bobbili SJ, Ventura CAA. Health care providers and people with mental illness: An integrative review on anti-stigma interventions. *International Journal of Social Psychiatry* 2021; **67**: 840–53.
- Tiali M, Scheibe A, Ruffieux Y, et al. Diagnosis and treatment of opioid related disorders in a South African private sector medical insurance scheme: a cohort study. *International Journal of Drug Policy* 2022.
- Seedat S, Williams DR, Herman AA, et al. Mental health service use among South Africans for mood, anxiety and substance use disorders. South African Medical Journal 2009; **99**: 346–52.
- Dovel K, Dworkin SL, Cornell M, Coates TJ, Yeatman S. Gendered health institutions: examining the organization of health services and men's use of HIV testing in Malawi. *J Int AIDS Soc* 2020; **23**. DOI:10.1002/jia2.25517.
- Cornell M, Majola M, Johnson LF, Dubula-Majola V. HIV services in sub-Saharan Africa: the greatest gap is men. *Lancet* 2021; **397**: 2130–2.
- Vogel, David L. Heimerdinger-Edwards SR, Hammer, Joseph H. Hubbard A. "Boys don't cry": Examination of the links between endorsement of masculine norms, self-stigma, and help-seeking attitudes for men from diverse backgrounds. *J Couns Psychol* 2011; **58**: 368–382.
- Latalova K, Kamaradova D, Prasko J. Perspectives on perceived stigma and self-stigma in adult male patients with depression. *Neuropsychiatr Dis Treat* 2014; **10**: 1399–405.
- Oliver, Maria Isabel Pearson, Nicky Coe, Nicola Gunnell D. Help-seeking behaviour in men and women with common mental health problems: Cross-sectional study. *The British Journal of Psychiatry* 2005; **186**: 297–301.

- Johnson LF, Dorrington RE, Laubscher R, et al. A comparison of death recording by health centres and civil registration in South Africans receiving antiretroviral treatment. *J Int AIDS Soc* 2015; **18**: 20628.
- Davis KAS, Sudlow CLM, Hotopf M. Can mental health diagnoses in administrative data be used for research? A systematic review of the accuracy of routinely collected diagnoses. *BMC Psychiatry* 2016; **16**: 263.
- Matzopoulos R, Prinsloo M, Pillay-Van Wyk V, *et al.* Injury-related mortality in south africa: A retrospective descriptive study of postmortem investigations. *Bull World Health Organ* 2015; **93**: 303–13.
- Hassim A, Heywood M, Berger J. The Private Health Care Sector. *Health and Democracy: A guide to human rights, health law and policy in post-apartheid South Africa* 2007; : 162–99.
- Ruffieux Y, Efthimiou O, Van Den Heuvel LL, *et al.* The treatment gap for mental disorders in adults enrolled in HIV treatment programmes in South Africa: A cohort study using linked electronic health records. *Epidemiol Psychiatr Sci* 2021. DOI:10.1017/S2045796021000196.

Table 1: Characteristics of people who did and did not receive mental health diagnoses before their end of follow-up

	Received mental health diagnoses	Without mental health diagnoses	Total
	N=282 926	N=787 257	N=1 070 183
Age at baseline, years			
15-19	32 015 (11.3%)	118 048 (15.0%)	150 063 (14.0%)
20-29	49 797 (17-6%)	173 373 (22.0%)	223 170 (20-9%)
30-39	69 255 (24.5%)	181 991 (23-1%)	251 246 (23-5%)
40-49	59 665 (21.1%)	136 445 (17-3%)	196 110 (18-3%)
50-59	41 652 (14-7%)	101 600 (12-9%)	143 252 (13-4%)
60-69	18 831 (6.7%)	49 003 (6.2%)	67 834 (6.3%)
70-84	11 711 (4.1%)	26 797 (3.4%)	38 508 (3.6%)
Median [IQR]	38-5 [28-5, 50-3]	35-2 [25-4, 48-5]	36-1 [26-3, 49-0]
Sex			
Male	114 377 (40-4%)	402 928 (51-2%)	517 305 (48-3%)
Female	168 549 (59-6%)	384 329 (48-8%)	552 878 (51.7%)
Calendar year at baseline			
2011-2013	188 817 (66-7%)	411 711 (52-3%)	600 528 (56-1%)
2014-2016	44 244 (15.6%)	134 390 (17-1%)	178 634 (16-7%)
2017-2019	47 144 (16-7%)	211 178 (26-8%)	258 322 (24-1%)
2020	2 721 (1.0%)	29 978 (3.8%)	32 699 (3.1%)
Died*			
Natural cause	9 662 (88-1%)	17 978 (84-8%)	27 640 (85.9%)
Unnatural cause	938 (8-6%)	2 240 (10-6%)	3 178 (9.9%)
Unknown cause	364 (3-3%)	977 (4.6%)	1 341 (4.2%)

Data are n (%) unless otherwise stated. |QR=interquartile range. *Denominators for percentages are total deaths in that group.

Table 2: Numbers and proportions of people who received mental health diagnoses during follow-up by sex

	Men N=517 305	Women N=552 878	Total N=1 070 183
Any Mental Health Diagnosis (F00-F99)	114 377 (22-1%)	168 549 (30-5%)	282 926 (26-4%)
Organic Mental Disorders (F00-F09)	3 863 (0.7%)	4 655 (0.8%)	8 518 (0.8%)
Substance Use Disorders (F10-F17, F19)	5 275 (1.0%)	2 042 (0.4%)	7 317 (0.7%)
Alcohol Use Disorders (F10)	2 757 (0.5%)	938 (0.2%)	3 695 (0.3%)
Drug Use Disorders (F11-F17, F19)	2 947 (0.6%)	1 226 (0.2%)	4 173 (0.4%)
Psychotic Disorders (F20-F29)	2 228 (0-4%)	2 324 (0.4%)	4 552 (0.4%)
Mood Disorders (F30-F39)	57 038 (11.0%)	98 835 (17-9%)	155 873 (14-6%)
Bipolar Disorders (F31)	6 786 (1.3%)	12 078 (2.2%)	18 864 (1.8%)
Depression (F32-F33, F34-1)	54 755 (10.6%)	95 785 (17-3%)	150 540 (14-1%)
Anxiety Disorders (F40-F48)	67 599 (13-1%)	110 405 (20.0%)	178 004 (16-6%)
Generalised Anxiety Disorders (F41·1)	11 521 (2-2%)	21 062 (3.8%)	32 583 (3.0%)
Post-traumatic Stress Disorders (F43·1)	5 362 (1.0%)	8 593 (1.6%)	13 955 (1.3%)
Developmental Disorders (F80-F89)	2 353 (0.5%)	1 646 (0.3%)	3 999 (0.4%)
Eating Disorders (F51)	459 (0.1%)	897 (0.2%)	1 356 (0.1%)
Personality Disorders (F60-F69)	653 (0.1%)	752 (0.1%)	1 405 (0.1%)

International Classification of Diseases, tenth revision code range of each diagnostic category is shown in parenthesis.

Table 3: Excess life years lost associated with mental health diagnoses by sex and cause of death

			Cause of	death	
Disorder type	Sex	All	Natural	Unnatural	Unknown
Any Mental Health Diagnosis	Men	3.83 [3.58; 4.10]	3.42 [3.17; 3.70]	0.45 [0.32; 0.59]	-0.04 [-0.11; 0.03]
	Women	2-19 [1-97; 2-41]	1.94 [1.73; 2.15]	0.22 [0.15; 0.28]	0.03 [-0.02; 0.09]
Organic Disorders	Men	11-49 [10-91; 12-01]	10-94 [10-26; 11-60]	0.62 [0.23; 1.11]	-0.07 [-0.21; 0.08]
	Women	9-98 [9-45; 10-61]	9-32 [8-72; 9-97]	0.47 [0.19; 0.75]	0.19 [0.01; 0.40]
Substance Use Disorders	Men	11.74 [10.35; 13.12]	8-17 [6-67; 9-68]	2.45 [1.48; 3.49]	1.13 [0.45; 1.88]
	Women	9.05 [6.88; 11.19]	7.13 [4.96; 9.26]	1.26 [0.29; 2.35]	0.65 [-0.07; 1.40]
Psychotic Disorders	Men	11-10 [9-52; 12-45]	9.69 [7.90; 11.25]	1.38 [0.38; 2.55]	0.03 [-0.36; 0.59]
	Women	9.01 [7.63; 10.41]	8.00 [6.58; 9.50]	0.79 [0.25; 1.37]	0.23 [-0.04; 0.56]
Mood Disorders	Men	4-31 [3-98; 4-66]	3.64 [3.28; 3.98]	0.69 [0.51; 0.86]	-0.02 [-0.11; 0.08]
	Women	2.49 [2.19; 2.78]	2.11 [1.83; 2.35]	0.30 [0.21; 0.38]	0.08 [0.02; 0.15]
Anxiety Disorders	Men	2.78 [2.43; 3.17]	2.45 [2.10; 2.82]	0.41 [0.25; 0.58]	-0.08 [-0.17; 0.01]
	Women	1.39 [1.12; 1.68]	1.17 [0.90; 1.42]	0.24 [0.16; 0.33]	-0.01 [-0.07; 0.05]
Developmental Disorders	Men	7-15 [2-59; 11-46]	5.75 [1.53; 9.84]	1.56 [-1.47; 5.73]	-0-16 [-0-66; 0-85]
	Women	8-51 [4-84; 11-61]	8-83 [5-04; 12-07]	-0.49 [-0.54; -0.45]	0.17 [-0.36; 1.33]
Eating Disorders	Men	9-31 [5-38; 12-36]	10.91 [6.99; 13.96]	-1-11 [-1-21; -1-03]	-0-48 [-0-53; -0-44]
	Women	7.84 [4.44; 11.62]	6-21 [3-09; 9-64]	1.76 [-0.26; 3.98]	-0-14 [-0-30; 0-19]
Personality Disorders	Men	5-13 [1-16; 8-73]	4.59 [0.70; 8.32]	1.03 [-0.69; 3.07]	-0-49 [-0-53; -0-45]
	Women	2.73 [-0.32; 5.86]	1.83 [-1.12; 4.92]	1.17 [-0.32; 2.92]	-0-27 [-0-30; -0-24]
Alcohol Use Disorders	Men	11.50 [9.79; 13.07]	8-16 [6-33; 9-66]	2.49 [1.41; 3.60]	0.84 [0.13; 1.70]
	Women	10-24 [7-30; 13-09]	9.02 [6.40; 11.90]	1.25 [0.05; 2.76]	-0.03 [-0.29; 0.59]
Drug Use Disorders	Men	12-32 [9-69; 15-13]	8.76 [6.13; 11.70]	2.05 [0.58; 3.77]	1.52 [0.28; 2.84]
	Women	7-89 [5-05; 11-06]	4.94 [2.08; 8.17]	1.85 [0.34; 3.69]	1.10 [-0.03; 2.40]
Bipolar Disorders	Men	5-21 [4-12; 6-16]	3.61 [2.56; 4.64]	1.52 [0.90; 2.17]	0.08 [-0.23; 0.41]
	Women	4.64 [3.82; 5.44]	3-32 [2-51; 4-08]	0.82 [0.48; 1.14]	0.50 [0.24; 0.77]
Depressive Disorders	Men	4-34 [3-98; 4-68]	3.67 [3.30; 4.02]	0.69 [0.48; 0.87]	-0.02 [-0.11; 0.08]
	Women	2.47 [2.17; 2.74]	2.10 [1.83; 2.34]	0.30 [0.22; 0.38]	0.07 [0.00; 0.13]
Generalised Anxiety Disorders	Men	2.11 [1.39; 2.85]	1.77 [1.08; 2.43]	0.35 [0.03; 0.79]	-0.02 [-0.22; 0.20]
	Women	0.87 [0.40; 1.43]	0.61 [0.14; 1.17]	0.21 [0.03; 0.38]	0.05 [-0.07; 0.17]
Post-traumatic Stress Disorders	Men	3.61 [2.11; 5.14]	3.07 [1.59; 4.56]	0.54 [-0.01; 1.14]	-0.01 [-0.34; 0.53]
	Women	1.83 [0.64; 3.02]	1.54 [0.51; 2.69]	0.35 [0.05; 0.68]	-0.07 [-0.28; 0.25]

Data are excess life years lost and 95% confidence intervals.

Figure 1: Excess life years lost among people who received mental health diagnoses compared with people of the same sex without mental health diagnoses.

Data are stratified by sex and health care setting. Left panel shows data of people diagnosed in any health care setting, such as outpatient or hospital. Right panel shows data from people diagnosed in hospitals. Error bars represent 95% confidence intervals. Confidence limits with negative values are truncated at 0 in the figure. PTSD: Post-traumatic stress disorders




Figure 2: Adjusted hazard ratios comparing all-cause mortality among people with and without mental health diagnoses.

We adjusted all models for baseline age, and time-updated calendar year. We adjusted models combining both sexes for sex. Model 1 does not adjust for psychiatric comorbidity; Model 2 adjusts for psychiatric comorbidity. The x-axes are on a logarithmic scale.




Figure S1: Flow diagram showing selection of eligible individuals for analyses




Figure S2: Psychiatric comorbidity among beneficiaries with a mental health diagnosis

Percentage of beneficiaries with diagnoses shown on the x-axis among those with diagnoses shown on the y-axis. Darker colours represent higher values. Org=organic mental disorders, SU=substance use disorders, psy=psychotic disorders, mood=mood disorders, anx=anxiety disorders, dev=developmental disorders, pers=personality disorders.




Table S1: Number and proportion of people who received mental health diagnoses in hospital settings during follow-up by sex

	Men N=517 305	Women N=552 878	Total N=1 070 183
Any Mental Health Diagnosis (F00-F99)	17 412 (3.4%)	28 263 (5-1%)	45 675 (4.3%)
Organic Mental Disorders (F00-F09)	1 951 (0.4%)	2 131 (0.4%)	4 082 (0.4%)
Substance Use Disorders (F10-F17, F19)	4 093 (0.8%)	1 216 (0.2%)	5 309 (0.5%)
Alcohol Use Disorders (F10)	2 145 (0.4%)	596 (0.1%)	2 741 (0.3%)
Drug Use Disorders (F11-F17, F19)	2 236 (0.4%)	687 (0.1%)	2 923 (0.3%)
Psychotic Disorders (F20-F29)	939 (0.2%)	863 (0.2%)	1 802 (0-2%)
Mood Disorders (F30-F39)	12 796 (2.5%)	24 752 (4.5%)	37 548 (3.5%)
Bipolar Disorders (F31)	2 351 (0.5%)	4 355 (0.8%)	6 706 (0.6%)
Depression (F32-F33, F34-1)	11 590 (2-2%)	22 803 (4.1%)	34 393 (3.2%)
Anxiety Disorders (F40-F48)	2 123 (0.4%)	5 058 (0.9%)	7 181 (0.7%)
Generalised Anxiety Disorders (F41·1)	373 (0.1%)	762 (0.1%)	1 135 (0-1%)
Post-traumatic Stress Disorders (F43-1)	421 (0.1%)	964 (0.2%)	1 385 (0.1%)
Developmental Disorders (F80-F89)	58 (0.0%)	44 (0.0%)	102 (0.0%)
Eating Disorders (F51)	20 (0.0%)	91 (0.0%)	111 (0.0%)
Personality Disorders (F60-F69)	105 (0.0%)	157 (0.0%)	262 (0.0%)

International Classification of Diseases, tenth revision code range of each diagnostic category is shown in parenthesis.

Table S2: Number and proportion of people who received psychiatric medication during follow-up by sex

	Men	Women	Total
	N=517 305	N=552 878	N=1 070 183
Any Psychiatric Medication	148 221 (28.7%)	224 096 (40.5%)	372 317 (34.8%)
Substance Use Medication	3 262 (0.6%)	2 281 (0.4%)	5 543 (0.5%)
Antidepressant	89 882 (17.4%)	148 475 (26.9%)	238 357 (22-3%)
Anxiolytic	90 114 (17-4%)	146 137 (26-4%)	236 251 (22-1%)
Antipsychotic	37 002 (7.2%)	64 707 (11.7%)	10 1709 (9.5%)

Table S3: Excess life years lost associated with mental health diagnoses from hospital settings by sex and cause of death

		Cause of death							
Disorder type	Sex	All	Natural	Unnatural	Unknown				
Any Mental Health Diagnosis	Men	12.15 [11.59; 12.70]	10-40 [9-75; 10-97]	1.68 [1.27; 2.15]	0.07 [-0.10; 0.28]				
	Women	8-67 [8-20; 9-13]	7.71 [7.25; 8.18]	0.70 [0.49; 0.90]	0-26 [0-11; 0-40]				
Organic Disorders	Men	12-12 [11-46; 12-70]	11-86 [11-10; 12-52]	0-29 [-0-09; 0-78]	-0.02 [-0.19; 0.19]				
	Women	10-32 [9-71; 10-95]	9-91 [9-27; 10-62]	0.24 [0.03; 0.44]	0.17 [0.00; 0.36]				
Substance Use Disorders	Men	12-94 [11-24; 14-38]	9.00 [7.09; 10.62]	2.56 [1.36; 3.68]	1.38 [0.50; 2.37]				
	Women	11-67 [8-47; 14-60]	8-59 [5-44; 11-80]	2.06 [0.47; 3.74]	1.02 [-0.09; 2.22]				
Psychotic Disorders	Men	15-29 [12-79; 17-61]	13.96 [10.99; 16.55]	1.82 [0.11; 3.87]	-0.50 [-0.54; -0.44]				
	Women	13-69 [11-54; 15-75]	12-29 [9-93; 14-91]	1.52 [0.39; 2.62]	-0.12 [-0.26; 0.21]				
Mood Disorders	Men	10-17 [9-42; 10-90]	8.36 [7.62; 9.04]	1.77 [1.27; 2.31]	0.04 [-0.17; 0.27]				
	Women	7-13 [6-54; 7-69]	6-10 [5-54; 6-66]	0.76 [0.51; 0.97]	0.27 [0.10; 0.43]				
Anxiety Disorders	Men	11-96 [10-37; 13-58]	9-86 [8-28; 11-49]	2.04 [0.97; 3.41]	0.06 [-0.37; 0.58]				
	Women	7.97 [6.53; 9.08]	6.63 [5.22; 7.88]	1.04 [0.50; 1.69]	0.29 [-0.11; 0.76]				
Developmental Disorders	Men	5.63 [-10.83; 19.03]	7-83 [-8-61; 21-21]	-1-66 [-1-89; -1-40]	-0.54 [-0.60; -0.48]				
	Women	18-84 [3-24; 28-71]	9.62 [-4.49; 24.80]	-0-37 [-0-47; -0-28]	9.59 [-0.30; 26.08]				
Eating Disorders	Men	15-14 [-10-88; 19-97]	16-81 [-8-94; 21-72]	-1-18 [-1-54; -0-84]	-0.49 [-0.56; -0.42]				
	Women	21.17 [16.38; 25.18]	11-07 [2-81; 17-27]	8-91 [-0-40; 18-71]	1.19 [-0.32; 4.82]				
Personality Disorders	Men	10-19 [-2-39; 16-26]	6-41 [-4-36; 12-84]	4-28 [-1-17; 11-07]	-0.50 [-0.55; -0.45]				
	Women	9-41 [-0-34; 15-68]	6.45 [-2.63; 12.56]	3-24 [-0-35; 8-67]	-0.28 [-0.31; -0.25]				
Alcohol Use Disorders	Men	12.06 [10.20; 13.73]	8.74 [6.79; 10.45]	2-25 [1-09; 3-42]	1.07 [0.18; 2.17]				
	Women	11-22 [7-29; 15-03]	8-69 [4-45; 12-82]	2.32 [0.29; 4.68]	0.21 [-0.29; 1.41]				
Drug Use Disorders	Men	15.01 [10.53; 18.04]	11-34 [7-00; 14-38]	2.19 [0.42; 4.36]	1.48 [0.10; 3.07]				
	Women	10-83 [6-63; 15-44]	7-10 [2-97; 12-05]	1.92 [0.11; 4.26]	1.80 [-0.27; 4.11]				
Bipolar Disorders	Men	9-69 [8-00; 11-45]	6.02 [4.14; 7.96]	3-04 [1-62; 4-65]	0.63 [-0.19; 1.54]				
	Women	8-17 [6-68; 9-51]	5.80 [4.33; 7.16]	1.64 [0.90; 2.33]	0.74 [0.18; 1.36]				
Depressive Disorders	Men	10-21 [9-42; 10-94]	8.52 [7.67; 9.22]	1.71 [1.20; 2.26]	-0.02 [-0.22; 0.20]				
	Women	7-15 [6-57; 7-75]	6-17 [5-59; 6-77]	0.70 [0.45; 0.94]	0.27 [0.10; 0.45]				
Generalised Anxiety Disorders	Men	6.55 [-4.17; 9.56]	7-19 [-3-33; 10-34]	-0.14 [-1.23; 2.11]	-0.50 [-0.54; -0.46]				
	Women	6.58 [3.12; 9.94]	5-45 [1-77; 8-65]	0.70 [-0.31; 2.26]	0.43 [-0.29; 2.53]				
Post-traumatic Stress Disorders	Men	13.08 [0.70; 15.84]	7-36 [-4-82; 9-96]	4.32 [1.14; 7.70]	1.40 [-0.50; 3.59]				
	Women	0.05 [-3.64; 4.45]	-2-17 [-5-13; 1-67]	2.51 [0.51; 5.06]	-0-28 [-0-31; -0-25]				

Table S4: Excess life years lost associated with psychiatric medication by sex and cause of death

		Cause of death						
Medication type	Sex	All	Natural	Unnatural	Unknown			
Any	Men	4.05 [3.79; 4.27]	3-90 [3-66; 4-12]	0.22 [0.13; 0.32]	-0.07 [-0.14; 0.00]			
	Women	2.26 [2.05; 2.48]	2.13 [1.94; 2.34]	0-10 [0-04; 0-15]	0.03 [-0.02; 0.07]			
Antidepressant	Men	4-49 [4-22; 4-77]	4-20 [3-92; 4-46]	0.36 [0.25; 0.49]	-0.07 [-0.14; 0.01]			
	Women	2.50 [2.27; 2.74]	2.32 [2.11; 2.54]	0-14 [0-08; 0-20]	0.04 [-0.02; 0.09]			
Antipsychotic	Men	7-16 [6-76; 7-53]	6.77 [6.38; 7.13]	0.35 [0.16; 0.55]	0.03 [-0.09; 0.14]			
	Women	4-53 [4-21; 4-88]	4-18 [3-89; 4-53]	0.25 [0.15; 0.36]	0.09 [0.01; 0.17]			
Anxiolytic	Men	3.85 [3.57; 4.10]	3.73 [3.47; 4.00]	0.19 [0.07; 0.30]	-0-07 [-0-16; 0-01]			
	Women	2.20 [1.96; 2.44]	2.05 [1.83; 2.28]	0-14 [0-07; 0-20]	0.02 [-0.04; 0.07]			
Substance Use	Men	3-34 [1-42; 5-03]	3-42 [1-64; 5-20]	0.07 [-0.54; 0.83]	-0-15 [-0-47; 0-23]			
	Women	4-36 [2-41; 6-33]	4-15 [2-19; 6-02]	0.13 [-0.27; 0.64]	0.09 [-0.26; 0.68]			

Table S5: Excess life years lost associated with mental health diagnoses by sex and cause of death. The exposed groups include only individuals with exactly one diagnosis of the given type

		Cause of death							
Disorder type	Sex	All	Natural	Unnatural	Unknown				
Any Mental Health Diagnosis	Men	5.61 [5.17; 6.10]	5.09 [4.63; 5.55]	0.44 [0.21; 0.69]	0.08 [-0.06; 0.24]				
	Women	4-41 [3-96; 4-84]	4.04 [3.60; 4.49]	0.36 [0.21; 0.51]	0.02 [-0.09; 0.12]				
Organic Disorders	Men	13-32 [12-50; 14-19]	12.29 [11.26; 13.30]	1.08 [0.33; 1.94]	-0.06 [-0.27; 0.22]				
	Women	11.70 [10.84; 12.64]	11.04 [10.14; 12.00]	0.46 [0.07; 0.88]	0-20 [-0-04; 0-49]				
Substance Use Disorders	Men	12-41 [10-23; 14-90]	9.99 [7.38; 12.42]	2.04 [0.46; 3.83]	0.38 [-0.43; 1.46]				
	Women	8-85 [5-60; 12-23]	7.71 [4.47; 11.24]	0.62 [-0.33; 1.97]	0.52 [-0.28; 1.60]				
Psychotic Disorders	Men	12-11 [9-84; 14-39]	11-15 [8-86; 13-40]	0.95 [-0.69; 2.83]	0.00 [-0.48; 1.03]				
	Women	10-69 [7-94; 13-07]	9.84 [6.99; 12.47]	0.53 [-0.27; 1.58]	0.31 [-0.25; 1.03]				
Mood Disorders	Men	6.53 [5.83; 7.14]	5.74 [5.05; 6.33]	0.78 [0.44; 1.10]	0.01 [-0.15; 0.19]				
	Women	4.66 [4.01; 5.25]	4-16 [3-56; 4-75]	0.37 [0.18; 0.56]	0-13 [-0-03; 0-29]				
Anxiety Disorders	Men	4.24 [3.76; 4.79]	3.64 [3.14; 4.13]	0.56 [0.31; 0.84]	0.05 [-0.10; 0.20]				
	Women	2.91 [2.43; 3.33]	2.58 [2.11; 3.00]	0.41 [0.26; 0.57]	-0.08 [-0.16; 0.01]				
Developmental Disorders	Men	3.26 [-3.27; 9.52]	4.74 [-1.42; 11.39]	-0.89 [-1.90; 1.42]	-0.59 [-0.64; -0.54]				
	Women	6.53 [1.17; 11.25]	6.50 [1.27; 11.52]	-0-42 [-0-47; -0-38]	0.46 [-0.34; 2.31]				
Eating Disorders	Men	10-64 [6-05; 13-64]	12-29 [7-69; 15-32]	-1-16 [-1-26; -1-06]	-0.49 [-0.53; -0.45]				
	Women	7-46 [2-96; 11-39]	6.40 [2.24; 10.21]	1-34 [-0-33; 4-29]	-0.28 [-0.31; -0.24]				
Personality Disorders	Men	5.01 [0.59; 9.28]	4-58 [0-04; 8-41]	0.92 [-0.88; 3.28]	-0.49 [-0.53; -0.45]				
	Women	3-32 [-0-44; 7-35]	1.78 [-1.46; 5.60]	1.82 [-0.32; 4.36]	-0.27 [-0.30; -0.24]				
Alcohol Use Disorders	Men	12-62 [9-21; 15-42]	8.50 [5.33; 11.61]	3.15 [1.08; 5.37]	0.98 [-0.18; 2.57]				
	Women	9-27 [4-33; 14-37]	7.30 [2.72; 12.33]	2-24 [-0-33; 5-95]	-0.27 [-0.30; -0.24]				
Drug Use Disorders	Men	14-46 [10-53; 17-03]	12-84 [8-32; 15-80]	2.15 [-0.12; 5.26]	-0.53 [-0.58; -0.06]				
	Women	7.68 [2.97; 12.04]	6.43 [1.78; 11.29]	0.39 [-0.34; 1.79]	0.86 [-0.28; 2.45]				
Bipolar Disorders	Men	4.79 [2.69; 6.74]	3-37 [1-12; 5-39]	1.36 [0.12; 2.67]	0.05 [-0.45; 0.86]				
	Women	7.04 [5.46; 8.64]	5-47 [3-95; 7-12]	0.81 [0.17; 1.55]	0.77 [0.11; 1.42]				
Depressive Disorders	Men	6.53 [5.85; 7.14]	5.77 [5.07; 6.39]	0.76 [0.43; 1.10]	0.00 [-0.17; 0.17]				
	Women	4.70 [4.07; 5.30]	4-25 [3-67; 4-86]	0.35 [0.16; 0.53]	0-11 [-0-04; 0-26]				
Generalised Anxiety Disorders	Men	2.53 [1.43; 3.52]	2.38 [1.35; 3.39]	0-18 [-0-28; 0-68]	-0.03 [-0.31; 0.30]				
	Women	1.14 [0.47; 2.05]	1.02 [0.28; 1.92]	0-14 [-0-06; 0-36]	-0.01 [-0.16; 0.16]				
Post-traumatic Stress Disorders	Men	3.82 [1.84; 5.73]	2.94 [1.13; 4.81]	0.84 [0.05; 1.70]	0.04 [-0.39; 0.53]				
	Women	1.04 [-0.48; 2.60]	0.93 [-0.43; 2.55]	0-21 [-0-12; 0-61]	-0-10 [-0-29; 0-32]				

Table S6: Excess life years lost associated with mental health diagnoses by sex and cause of death. People who died within one year of the end of their insurance coverage are not censored at the end of the coverage.

			Cause of d	leath	
Disorder type	Sex	All	Natural	Unnatural	Unknown
Any Mental Health Diagnosis	Men	3.69 [3.41; 3.96]	3.21 [2.94; 3.48]	0.50 [0.35; 0.65]	-0.02 [-0.09; 0.06]
	Women	2.07 [1.87; 2.29]	1.82 [1.61; 2.04]	0.22 [0.15; 0.29]	0.03 [-0.02; 0.09]
Organic Disorders	Men	11.27 [10.75; 11.90]	10.72 [10.01; 11.38]	0.63 [0.18; 1.16]	-0.08 [-0.21; 0.09]
	Women	10-02 [9-47; 10-61]	9-39 [8-76; 10-00]	0.47 [0.18; 0.75]	0.17 [0.01; 0.37]
Substance Use Disorders	Men	12.04 [10.59; 13.35]	7.85 [6.44; 9.36]	3.08 [2.04; 4.12]	1.11 [0.37; 1.85]
	Women	9.63 [7.67; 11.55]	7.50 [5.38; 9.64]	1.34 [0.45; 2.32]	0.79 [0.06; 1.62]
Psychotic Disorders	Men	11-39 [9-88; 12-80]	9.79 [8.44; 11.36]	1.60 [0.60; 2.88]	0.00 [-0.39; 0.50]
	Women	9-35 [8-03; 10-63]	8-29 [6-88; 9-65]	0.81 [0.24; 1.47]	0.25 [-0.04; 0.62]
Mood Disorders	Men	4.15 [3.79; 4.50]	3.39 [3.05; 3.73]	0.76 [0.57; 0.96]	0.00 [-0.09; 0.11]
	Women	2.33 [2.08; 2.62]	1.94 [1.68; 2.22]	0.31 [0.21; 0.40]	0.08 [0.01; 0.15]
Anxiety Disorders	Men	2.59 [2.26; 2.96]	2.23 [1.91; 2.59]	0.43 [0.25; 0.59]	-0.07 [-0.15; 0.03]
	Women	1.31 [1.04; 1.57]	1.08 [0.83; 1.35]	0.24 [0.14; 0.34]	-0.02 [-0.08; 0.05]
Developmental Disorders	Men	7-15 [2-67; 12-12]	5.20 [1.52; 9.03]	2.18 [-1.38; 7.02]	-0.23 [-0.66; 0.72]
	Women	7.86 [4.17; 11.19]	8-28 [4-52; 11-40]	-0.58 [-0.63; -0.53]	0.16 [-0.36; 1.33]
Eating Disorders	Men	8-48 [5-44; 11-68]	10.28 [7.22; 13.49]	-1-32 [-1-42; -1-21]	-0-48 [-0-52; -0-44]
	Women	7-39 [4-07; 10-40]	5.84 [2.61; 9.01]	1-69 [-0-03; 4-21]	-0-14 [-0-31; 0-21]
Personality Disorders	Men	4.76 [1.31; 8.12]	3.59 [0.42; 7.11]	1-29 [-0-58; 3-66]	-0-12 [-0-52; 0-78]
	Women	3-29 [-0-13; 6-95]	2.50 [-0.86; 5.99]	1.07 [-0.36; 2.90]	-0-27 [-0-31; -0-24]
Alcohol Use Disorders	Men	11.80 [10.23; 13.30]	8-14 [6-62; 9-91]	2.90 [1.78; 4.13]	0.75 [0.04; 1.57]
	Women	10.84 [7.94; 13.69]	9-48 [6-44; 12-44]	1.41 [0.15; 2.87]	-0.05 [-0.29; 0.54]
Drug Use Disorders	Men	12-31 [9-29; 14-92]	7.57 [4.44; 10.43]	3.09 [1.26; 4.91]	1.66 [0.32; 3.15]
	Women	8-20 [5-39; 11-34]	5.07 [2.46; 8.04]	1.74 [0.29; 3.62]	1.38 [0.11; 2.78]
Bipolar Disorders	Men	5.36 [4.48; 6.39]	3.54 [2.60; 4.63]	1.67 [0.96; 2.39]	0-15 [-0-16; 0-48]
	Women	4.54 [3.69; 5.36]	3.15 [2.43; 3.92]	0.86 [0.55; 1.19]	0.52 [0.25; 0.86]
Depressive Disorders	Men	4.17 [3.83; 4.53]	3-42 [3-06; 3-77]	0.76 [0.57; 0.97]	-0.01 [-0.10; 0.11]
	Women	2.31 [2.05; 2.61]	1.94 [1.67; 2.24]	0.31 [0.21; 0.40]	0.06 [-0.01; 0.13]
Generalised Anxiety Disorders	Men	1.81 [1.07; 2.50]	1.44 [0.71; 2.18]	0.40 [0.02; 0.78]	-0.03 [-0.22; 0.18]
	Women	0.71 [0.18; 1.20]	0.43 [-0.04; 0.92]	0-22 [0-06; 0-41]	0.06 [-0.07; 0.21]
Post-traumatic Stress Disorders	Men	3.67 [2.18; 5.08]	3-10 [1-60; 4-71]	0.59 [0.01; 1.23]	-0.02 [-0.39; 0.41]
	Women	1.72 [0.55; 2.79]	1.43 [0.43; 2.46]	0.36 [0.05; 0.79]	-0.07 [-0.29; 0.26]

Table S7: Hazard ratios per follow-up time interval comparing all-cause mortality among individuals with mental health diagnoses to those without

		Year of follow-up)
Disorder type	First	Second	Third and beyond
Any Mental Health Diagnosis	1.96 [1.82; 2.10]	1.72 [1.61; 1.84]	1.60 [1.56; 1.65]
Organic Disorders	8-12 [6-85; 9-63]	6-31 [5-48; 7-28]	4.74 [4.49; 5.00]
Substance Use Disorders	3-16 [2-19; 4-57]	1.98 [1.39; 2.81]	1.77 [1.58; 1.99]
Psychotic Disorders	1.81 [1.26; 2.61]	1.58 [1.14; 2.18]	1.47 [1.32; 1.64]
Mood Disorders	1.53 [1.38; 1.69]	1.42 [1.29; 1.55]	1.30 [1.26; 1.35]
Anxiety Disorders	1.11 [0.98; 1.26]	1.06 [0.96; 1.17]	1.02 [0.99; 1.06]
Developmental Disorders	1.06 [0.39; 2.86]	1.23 [0.55; 2.76]	1-28 [0-98; 1-66]
Personality Disorders	1.55 [0.58; 4.16]	0.20 [0.03; 1.39]	1.06 [0.80; 1.40]

 $The \ models \ were \ adjusted \ for \ sex, \ baseline \ age, \ psychiatric \ comorbidity, \ and \ time-updated \ calendar \ year.$

Table S8: Hazard ratios (HR) comparing mortality (all-cause, natural deaths, unnatural deaths) among individuals with mental health diagnoses to those without unadjusted and adjusted for psychiatric comorbidity

Disorder type	Cause of death	Sex	HR, unadjusted for psychiatric comorbidity	HR, adjusted for psychiatric comorbidity	p-value for interaction with sex
Any Mental Health Diagnosis	All	Both	1-65 [1-61; 1-69]	-	<0.001
		Female	1.55 [1.50; 1.61]	-	-
		Male	1.74 [1.68; 1.80]	-	-
	Natural	Both	1.66 [1.62; 1.70]	-	<0.001
		Female	1.54 [1.48; 1.60]	-	-
		Male	1.77 [1.71; 1.84]	-	-
	Unnatural	Both	1-60 [1-48; 1-74]	-	0.087
		Female	1.71 [1.46; 2.00]	-	-
		Male	1.56 [1.42; 1.72]	-	-
Organic Disorders	AII	Both	6.01 [5.74; 6.29]	5.04 [4.80; 5.29]	0.933
-		Female	6.02 [5.63; 6.43]	5-19 [4-84; 5-57]	-
		Male	6.01 [5.64; 6.40]	4.90 [4.58; 5.23]	-
	Natural	Both	6.20 [5.91; 6.50]	5.30 [5.04; 5.57]	0.049
		Female	6.08 [5.67; 6.50]	5.34 [4.97; 5.74]	-
		Male	6.32 [5.92; 6.75]	5.25 [4.90; 5.62]	-
	Unnatural	Both	3.63 [2.79; 4.73]	2.49 [1.89; 3.27]	0.020
	2	Female	5.13 [3.37; 7.80]	3.44 [2.23; 5.32]	-
		Male	3.02 [2.14; 4.26]	2.09 [1.46; 2.97]	_
Substance Use Disorders	All	Both	2.93 [2.64; 3.25]	1.84 [1.65; 2.05]	0.247
AUDOLATION CON DISCULCIO	All	Female	2.63 [2.15; 3.23]	1.57 [1.28; 1.93]	-
		Male			-
	Motural		3.05 [2.70; 3.45]	1.94 [1.71; 2.20]	0.207
	Natural	Both	2.68 [2.37; 3.02]	1.66 [1.47; 1.87]	0.307
		Female	2.42 [1.94; 3.02]	1.45 [1.16; 1.81]	-
		Male	2.80 [2.43; 3.23]	1.74 [1.50; 2.01]	-
	Unnatural	Both	3.64 [2.83; 4.68]	2.38 [1.83; 3.09]	0.392
		Female	4.41 [2.28; 8.51]	2.49 [1.27; 4.88]	-
		Male	3.53 [2.69; 4.63]	2.45 [1.84; 3.25]	-
Sychotic Disorders	All	Both	3.12 [2.83; 3.43]	1.48 [1.34; 1.64]	0.807
		Female	3.08 [2.69; 3.54]	1.56 [1.35; 1.79]	-
		Male	3.15 [2.75; 3.60]	1.41 [1.23; 1.63]	-
	Natural	Both	3-13 [2-83; 3-47]	1.48 [1.33; 1.64]	0.289
		Female	3.00 [2.60; 3.48]	1.52 [1.30; 1.76]	-
		Male	3.27 [2.83; 3.77]	1.43 [1.23; 1.66]	-
	Unnatural	Both	2.91 [2.05; 4.12]	1.57 [1.09; 2.25]	0.134
		Female	4.02 [2.27; 7.12]	2.08 [1.15; 3.76]	-
		Male	2.49 [1.60; 3.88]	1.38 [0.88; 2.18]	-
Mood Disorders	All	Both	1.59 [1.55; 1.64]	1.34 [1.30; 1.38]	<0.001
		Female	1.49 [1.43; 1.56]	1.28 [1.23; 1.34]	-
		Male	1.70 [1.63; 1.77]	1-39 [1-34; 1-46]	-
	Natural	Both	1.56 [1.52; 1.61]	1.31 [1.26; 1.35]	<0.001
		Female	1.46 [1.39; 1.52]	1.25 [1.19; 1.31]	-
		Male	1.69 [1.61; 1.76]	1.37 [1.31; 1.44]	-
	Unnatural	Both	1.85 [1.69; 2.04]	1.58 [1.43; 1.76]	0.113
		Female	1.99 [1.68; 2.35]	1.70 [1.41; 2.03]	-
		Male	1.79 [1.60; 2.01]	1.53 [1.35; 1.74]	-
Inxiety Disorders	All	Both	1.24 [1.20; 1.27]	1.03 [0.99; 1.06]	<0.001
. ,		Female	1.17 [1.12; 1.22]	0.98 [0.94; 1.03]	-
		Male	1.31 [1.25; 1.36]	1.07 [1.02; 1.12]	-
	Natural	Both	1.21 [1.17; 1.25]	1.01 [0.97; 1.04]	<0·001
	ivaturai	Female			
			1·14 [1·09; 1·20] 1·29 [1·23; 1·35]	0.97 [0.92; 1.01]	-
		Male	1.52 [1.53, 1.35]	1.05 [1.00; 1.11]	-
	l longture!	Doth	4 46 [4 20: 4 60]	4 20 [4 00, 4 20]	0.111
	Unnatural	Both Female	1·46 [1·32; 1·60] 1·56 [1·32; 1·86]	1·20 [1·08; 1·33] 1·25 [1·04; 1·51]	0·111 -

Developmental Disorders	All	Both	1.67 [1.31; 2.12]	1.24 [0.97; 1.58]	0.474
		Female	1.83 [1.28; 2.62]	1.41 [0.98; 2.01]	-
		Male	1.55 [1.12; 2.15]	1.14 [0.82; 1.58]	-
	Natural	Both	1.94 [1.50; 2.50]	1.40 [1.08; 1.80]	0.512
		Female	2.05 [1.42; 2.95]	1.56 [1.08; 2.24]	-
		Male	1.84 [1.29; 2.64]	1.27 [0.88; 1.82]	_
	Unnatural				
	Unnatural	Both	0-66 [0-27; 1-59]	0.54 [0.22; 1.30]	0.963
		Female			-
		Male	0.85 [0.35; 2.04]	0.70 [0.29; 1.70]	-
Personality Disorders	All	Both	1.65 [1.27; 2.15]	1.00 [0.76; 1.30]	0.618
		Female	1.53 [1.01; 2.32]	0.96 [0.63; 1.46]	-
		Male	1.75 [1.24; 2.46]	1.03 [0.73; 1.45]	-
	Natural	Both	1.60 [1.19; 2.13]	0.96 [0.72; 1.29]	0.568
		Female	1.45 [0.93; 2.28]	0.91 [0.58; 1.42]	-
		Male	1.71 [1.17; 2.50]	1.01 [0.69; 1.47]	-
	Unnatural	Both	2.62 [1.36; 5.04]	1.63 [0.84; 3.14]	0.594
		Female	3-26 [1-05; 10-15]	2.13 [0.68; 6.64]	-
		Male	2.38 [1.07; 5.31]	1.49 [0.66; 3.33]	_
Alcohol Use Disorders	All	Both	3.22 [2.84; 3.65]	-	0.427
Alcohol Ose Disorders	All	Female	2.93 [2.24; 3.83]	- -	-
	Netimel	Male	3.31 [2.87; 3.81]	-	-
	Natural	Both	3.01 [2.61; 3.46]	-	0.616
		Female	2.84 [2.14; 3.77]	-	-
		Male	3.07 [2.60; 3.61]	-	-
	Unnatural	Both	4-21 [3-10; 5-71]	-	0.570
		Female	4.98 [2.06; 12.02]	-	-
		Male	4-12 [2-97; 5-71]	-	-
Drug Use Disorders	All	Both	2.64 [2.23; 3.11]	-	0.319
		Female	2.32 [1.73; 3.11]	-	-
		Male	2.82 [2.30; 3.45]	-	-
	Natural	Both	2.23 [1.82; 2.73]	_	0.325
		Female	1.93 [1.37; 2.70]	-	-
		Male	2.45 [1.90; 3.15]	-	_
	Unnatural	Both	3.45 [2.40; 4.95]	-	0.207
	Official	Female	5.16 [2.31; 11.55]	-	-
				-	-
Dinalar Dinardara	A.II	Male	3.18 [2.12; 4.77]	-	
Bipolar Disorders	All	Both	1.69 [1.57; 1.82]	-	0.770
		Female	1.71 [1.55; 1.88]	-	-
		Male	1.67 [1.50; 1.86]	-	-
	Natural	Both	1.54 [1.42; 1.67]	-	0.816
		Female	1.54 [1.38; 1.71]	-	-
		Male	1.55 [1.37; 1.74]	-	-
	Unnatural	Both	2.77 [2.28; 3.37]	-	0.103
		Female	3.26 [2.41; 4.40]	-	-
		Male	2.50 [1.93; 3.23]	-	-
Depressive Disorders	All	Both	1.59 [1.54; 1.63]	-	<0.001
·		Female	1.49 [1.43; 1.55]	-	-
		Male	1.70 [1.63; 1.77]	-	-
	Natural	Both	1.56 [1.51; 1.61]	_	<0.001
	Hatarai	Female	1.45 [1.39; 1.52]	_	-
		Male			
	Llanatural		1.69 [1.61; 1.76]	-	- 0.400
	Unnatural	Both	1.85 [1.68; 2.03]	-	0-126
		Female	1.97 [1.67; 2.33]	-	-
		Male	1.79 [1.59; 2.01]	-	-
Generalised Anxiety Disorders	All	Both	1-12 [1-05; 1-19]	-	0.108
		Female	1.07 [0.98; 1.16]	-	-
		Male	1.18 [1.08; 1.29]	-	-
	Natural	Both	1.09 [1.02; 1.16]	-	0.050
		Female	1.03 [0.95; 1.13]	-	-
		Male	1-16 [1-05; 1-28]	-	-
	Unnatural	Both	1-30 [1-06; 1-59]	-	0.500
			,1		

		Female	1.35 [0.97; 1.89]	-	-
		Male	1.27 [0.98; 1.64]	-	-
Post-traumatic Stress Disorders	All	Both	1.23 [1.11; 1.37]	-	0.449
		Female	1.19 [1.02; 1.38]	-	-
		Male	1-28 [1-10; 1-49]	-	-
	Natural	Both	1-20 [1-07; 1-35]	-	0.750
		Female	1-17 [1-00; 1-38]	-	-
		Male	1.23 [1.04; 1.45]	-	-
	Unnatural	Both	1.56 [1.17; 2.07]	-	0-697
		Female	1-61 [0-99; 2-62]	-	-
		Male	1.53 [1.08; 2.17]	-	-
Eating Disorders	All	Both	2.52 [1.99; 3.19]	-	0-899
		Female	2.56 [1.86; 3.52]	-	-
		Male	2.48 [1.74; 3.53]	-	-
	Natural	Both	2.65 [2.07; 3.40]	-	0-386
		Female	2.39 [1.69; 3.39]	-	-
		Male	2.98 [2.10; 4.24]	-	-
	Unnatural	Both	1.82 [0.76; 4.38]	-	0.959
		Female	4-68 [1-94; 11-29]	-	-
		Male	•	-	-

We adjusted all models for baseline age, and time-updated calendar year. The models combining both sexes were adjusted for sex. There were no deaths from unnatural causes among women with developmental disorders or among men with eating disorders; the corresponding HRs are not shown. Models adjusted for psychiatric comorbidity included binary indicators for organic mental disorders, substance use disorders, psychotic disorders, mood disorders, anxiety disorders, behavioural syndromes associated with physiological disturbances and physical factors, personality disorders, developmental disorders and behavioural disorders.

Table S9: Hazard ratios (HR) comparing mortality (all-cause and natural and unnatural deaths) among individuals with mental health diagnoses from hospital settings with those without unadjusted and adjusted for psychiatric comorbidity

Disorder type	Cause of death	Sex	HR, unadjusted for comorbidity	HR, adjusted for comorbidity	p-value for interaction with sex
Any Mental Health Diagnosis	All	Both	3.79 [3.66; 3.93]	-	<0.001
		Female	3.42 [3.25; 3.60]	-	-
		Male	4-22 [4-01; 4-44]	-	-
	Natural	Both	3.87 [3.72; 4.02]	-	<0.001
		Female	3.41 [3.23; 3.60]	-	-
		Male	4-43 [4-20; 4-68]	-	-
	Unnatural	Both	3.26 [2.87; 3.72]	-	0.464
		Female	3.35 [2.69; 4.17]	-	-
		Male	3.22 [2.75; 3.78]	-	-
Organic Disorders	All	Both	8-48 [8-03; 8-96]	6.81 [6.43; 7.22]	0.629
		Female	8-34 [7-70; 9-03]	6.91 [6.35; 7.52]	-
		Male	8.61 [7.99; 9.28]	6.73 [6.22; 7.28]	_
	Natural	Both	8.77 [8.29; 9.27]	7-21 [6-80; 7-65]	0.019
		Female	8.41 [7.75; 9.13]	7-13 [6-54; 7-78]	-
		Male	9.10 [8.43; 9.82]	7.27 [6.70; 7.88]	_
	Unnatural	Both	4.05 [2.78; 5.91]	2.50 [1.69; 3.68]	0.050
	Jiatarar	Female	6.16 [3.43; 11.05]	3.66 [2.00; 6.72]	-
		Male	3.23 [1.97; 5.31]	2.02 [1.22; 3.36]	-
Substance Use Disorders	All	Both	3.35 [2.97; 3.77]	1.97 [1.74; 2.22]	0.721
Substance Ose Disorders	All	Female	3.47 [2.70; 4.47]	1.79 [1.39; 2.31]	-
		Male	3.31 [2.89; 3.80]	1.99 [1.73; 2.29]	_
	Natural	Both	= =	1.75 [1.52; 2.02]	- 0.912
	ivaturai	Female	3.04 [2.65; 3.50]		0.912
			3.04 [2.29; 4.03]	1.56 [1.17; 2.08]	-
	l lonational	Male	3.05 [2.59; 3.58]	1.78 [1.51; 2.10]	-
	Unnatural	Both	3.95 [3.01; 5.20]	2.49 [1.87; 3.30]	0.095
		Female	6.51 [3.24; 13.10]	3.32 [1.62; 6.77]	-
B 1 (1 B) 1	A.II	Male	3.69 [2.74; 4.96]	2.47 [1.82; 3.37]	-
Psychotic Disorders	All	Both	4.50 [3.90; 5.18]	1.62 [1.40; 1.88]	0.804
		Female	4.58 [3.76; 5.58]	1.76 [1.44; 2.16]	-
		Male	4.41 [3.60; 5.41]	1.48 [1.20; 1.83]	-
	Natural	Both	4.62 [3.97; 5.37]	1.63 [1.40; 1.91]	0.677
		Female	4.51 [3.66; 5.55]	1.73 [1.40; 2.14]	-
		Male	4.74 [3.81; 5.89]	1.52 [1.22; 1.90]	-
	Unnatural	Both	4.39 [2.76; 6.98]	2.00 [1.24; 3.24]	0.059
		Female	7-44 [3-70; 14-97]	3-17 [1-53; 6-56]	-
		Male	3-30 [1-77; 6-15]	1.57 [0.83; 2.96]	-
Mood Disorders	All	Both	2.64 [2.52; 2.77]	1.80 [1.71; 1.90]	<0.001
		Female	2.44 [2.29; 2.60]	1.78 [1.66; 1.91]	-
		Male	2.92 [2.72; 3.13]	1.84 [1.70; 1.99]	-
	Natural	Both	2.59 [2.47; 2.73]	1.76 [1.66; 1.86]	<0.001
		Female	2.37 [2.21; 2.53]	1.72 [1.59; 1.85]	-
		Male	2.94 [2.73; 3.17]	1.82 [1.68; 1.98]	-
	Unnatural	Both	3.07 [2.65; 3.55]	2.26 [1.91; 2.66]	0.327
		Female	3.24 [2.57; 4.09]	2.45 [1.89; 3.17]	-
		Male	2.96 [2.45; 3.57]	2.12 [1.71; 2.62]	-
Anxiety Disorders	All	Both	2.80 [2.54; 3.10]	1.71 [1.54; 1.89]	0.006
· · · · · · · · · · · · · · · · · · ·		Female	2.51 [2.20; 2.86]	1.61 [1.40; 1.84]	-
		Male	3.33 [2.85; 3.88]	1.90 [1.62; 2.23]	-
	Natural	Both	2.73 [2.45; 3.04]	1.68 [1.50; 1.87]	0.004
		Female	2.42 [2.10; 2.79]	1.57 [1.35; 1.81]	-
		Male	3.32 [2.80; 3.93]	1.92 [1.61; 2.28]	-
	Unnatural	Both	3.60 [2.67; 4.86]	2.09 [1.53; 2.84]	0.713
	Jiatai ai	Female	3.68 [2.35; 5.75]	2.12 [1.33; 3.37]	-
				- 12 1°00, 0°01	

Developmental Disorders	All	Both	3.99 [2.15; 7.43]	2.59 [1.39; 4.82]	0.398
		Female	4.91 [2.34; 10.31]	3.17 [1.51; 6.67]	-
		Male	2.79 [0.90; 8.65]	1.81 [0.58; 5.61]	-
	Natural	Both	4.07 [2.12; 7.83]	2.64 [1.37; 5.09]	0.721
		Female	4.47 [2.01; 9.97]	2.88 [1.29; 6.44]	-
			= =		
		Male	3-46 [1-11; 10-72]	2.24 [0.72; 6.95]	-
	Unnatural	Both	•	•	•
		Female	•	•	-
		Male	•		-
Personality Disorders	All	Both	2.79 [1.71; 4.55]	1.22 [0.75; 2.00]	0.805
•		Female	2.99 [1.49; 5.97]	1.87 [0.94; 3.76]	-
		Male	2.61 [1.31; 5.23]	0.90 [0.45; 1.80]	_
	Natural	Both			0.709
	ivaturai		2.25 [1.25; 4.06]	1.04 [0.57; 1.87]	
		Female	2.51 [1.13; 5.58]	1.61 [0.72; 3.59]	-
		Male	2.00 [0.83; 4.82]	0.71 [0.30; 1.72]	-
	Unnatural	Both	7-65 [3-18; 18-39]	2.80 [1.15; 6.82]	0.624
		Female	9.98 [2.49; 40.02]	4.79 [1.18; 19.46]	-
		Male	6.62 [2.13; 20.54]	2.31 [0.73; 7.29]	-
Alcohol Use Disorders	All	Both	3.46 [3.00; 3.98]		0.990
		Female	3.46 [2.48; 4.82]	-	-
		Male		-	_
	Natural		3.46 [2.96; 4.04]	•	
	Natural	Both	3.21 [2.74; 3.77]	-	0.933
		Female	3-16 [2-20; 4-56]	-	-
		Male	3.23 [2.70; 3.86]	-	-
	Unnatural	Both	4.36 [3.11; 6.12]	-	0.126
		Female	7.89 [3.27; 19.04]	-	-
		Male	4.04 [2.80; 5.84]	-	_
Drug Use Disorders	All	Both	3.34 [2.75; 4.07]	_	0.859
Drug Coo Dicordoro	, ui	Female	= = =		-
			3.43 [2.38; 4.94]	-	-
		Male	3.31 [2.62; 4.19]	-	-
	Natural	Both	2.88 [2.25; 3.68]	-	0.987
		Female	2.78 [1.81; 4.27]	-	-
		Male	2.93 [2.17; 3.95]	-	-
	Unnatural	Both	3.82 [2.57; 5.68]	-	0.267
		Female	6.05 [2.26; 16.18]	-	-
		Male	3.57 [2.32; 5.50]	-	_
Bipolar Disorders	All	Both	2.42 [2.15; 2.71]	_	0.768
Dipolal Disorders	All		= =	_	0.700
		Female	2.39 [2.05; 2.77]		-
		Male	2.46 [2.06; 2.94]	-	-
	Natural	Both	2.08 [1.82; 2.37]	-	0.766
		Female	2.04 [1.72; 2.43]	-	-
		Male	2.13 [1.73; 2.63]	-	-
	Unnatural	Both	4.53 [3.47; 5.91]	-	0.133
		Female	5.51 [3.74; 8.12]	-	-
		Male	3.90 [2.70; 5.63]	_	_
Doprossivo Disordoro	ΛII				-0 001
Depressive Disorders	All	Both	2.65 [2.53; 2.78]	-	<0.001
		Female	2.46 [2.30; 2.62]	-	-
		Male	2.93 [2.73; 3.15]	-	-
	Natural	Both	2.62 [2.49; 2.76]	-	<0.001
		Female	2.40 [2.24; 2.57]	-	-
		Male	2.98 [2.75; 3.22]	-	-
	Unnatural	Both	2.93 [2.51; 3.42]	-	0.593
		Female	2.97 [2.32; 3.81]	_	
		Male	2.90 [2.38; 3.54]		
Consuling d Anniety Discussion	Δ.II		= =	-	- 0.000
Generalised Anxiety Disorders	All	Both	1.51 [1.08; 2.10]	-	0.396
		Female	1.68 [1.13; 2.51]	-	-
		Male	1-24 [0-68; 2-23]	-	-
	Natural	Both	1.52 [1.07; 2.16]	-	0.675
		Female	1.61 [1.05; 2.47]	-	-
		Male	1.37 [0.73; 2.54]	-	-
	Unnatural	Both	1.43 [0.46; 4.45]	-	0.325
	2		[5,0]		

		Female	2.45 [0.61; 9.82]	-	-
		Male	0.78 [0.11; 5.58]	-	-
Post-traumatic Stress Disorders	All	Both	1.74 [1.25; 2.41]	-	0.015
		Female	1.17 [0.71; 1.94]	-	-
		Male	2.65 [1.73; 4.07]	-	-
	Natural	Both	0.96 [0.60; 1.55]	-	0-156
		Female	0.70 [0.35; 1.40]	-	-
		Male	1.43 [0.74; 2.74]	-	-
	Unnatural	Both	6.68 [4.08; 10.94]	-	0.895
		Female	6.73 [3.19; 14.19]	-	-
		Male	6.65 [3.45; 12.81]	-	-
Eating Disorders	All	Both	9.90 [5.97; 16.43]	-	0.872
		Female	10.13 [5.75; 17.86]	-	-
		Male	9.07 [2.93; 28.15]	-	-
	Natural	Both	8.55 [4.73; 15.44]	-	0.540
		Female	7.70 [3.85; 15.42]	-	-
		Male	12.05 [3.88; 37.38]	-	-
	Unnatural	Both	17-20 [5-54; 53-45]	-	0.973
		Female	28-69 [9-21; 89-39]	-	-
		Male		-	-

We adjusted all models for baseline age, and time-updated calendar year. We adjusted the models combining both sexes for sex. There were no deaths from unnatural causes among men with developmental disorders or eating disorders, or among people of either sex with developmental disorders; corresponding HR are not shown. Models adjusted for psychiatric comorbidity included binary indicators for organic mental disorders, substance use disorders, psychotic disorders, mood disorders, anxiety disorders, behavioural syndromes associated with physiological disturbances and physical factors, personality disorders, developmental disorders and behavioural disorders.

Table S10: Hazard ratios (HR) comparing mortality (all-cause, natural deaths, unnatural deaths) among individuals prescribed psychiatric medication to those who were not prescribed psychiatric medication unadjusted and adjusted for psychiatric comorbidity

Medication type	Cause of death	Sex	HR, unadjusted for comorbidity	HR, adjusted for comorbidity	p-value for interaction with sex
Any Medication	All	Both	1.77 [1.73; 1.81]	-	<0.001
		Female	1.64 [1.58; 1.70]	-	-
		Male	1.87 [1.81; 1.93]	-	-
	Natural	Both	1.84 [1.79; 1.88]	-	<0.001
		Female	1.66 [1.59; 1.72]	-	-
		Male	1.99 [1.92; 2.06]	-	-
	Unnatural	Both	1.37 [1.26; 1.48]	-	0.537
		Female	1.33 [1.14; 1.56]	-	-
		Male	1.38 [1.25; 1.51]	-	-
Antidepressants	All	Both	1.63 [1.59; 1.67]	1.41 [1.37; 1.45]	<0.001
•		Female	1.51 [1.46; 1.57]	1.33 [1.28; 1.38]	-
		Male	1.74 [1.68; 1.79]	1.48 [1.43; 1.53]	-
	Natural	Both	1.64 [1.60; 1.69]	1.41 [1.37; 1.45]	<0.001
		Female	1.50 [1.45; 1.56]	1.32 [1.27; 1.38]	-
		Male	1.78 [1.72; 1.85]	1.50 [1.44; 1.56]	-
	Unnatural	Both	1.52 [1.40; 1.66]	1.41 [1.29; 1.55]	0.662
		Female	1.49 [1.27; 1.75]	1.32 [1.11; 1.56]	-
		Male	1.54 [1.39; 1.70]	1.45 [1.30; 1.62]	_
Antipsychotics	All	Both	2.18 [2.12; 2.24]	1.93 [1.87; 1.99]	<0.001
poyoouoc	7	Female	2.00 [1.92; 2.09]	1.81 [1.73; 1.89]	-
		Male	2.36 [2.27; 2.46]	2.05 [1.97; 2.14]	_
	Natural	Both	2.24 [2.17; 2.31]	1.98 [1.92; 2.04]	<0.001
	rvatarar	Female	2.01 [1.93; 2.10]	1.83 [1.75; 1.91]	-
		Male	2.49 [2.39; 2.60]	2.15 [2.05; 2.24]	_
	Unnatural	Both	1.56 [1.39; 1.75]	1.39 [1.24; 1.57]	0.082
	Omatarar	Female	1.70 [1.41; 2.07]	1.53 [1.25; 1.86]	-
		Male	1.48 [1.28; 1.71]	1.32 [1.14; 1.53]	_
Anxiolytics	All	Both	1.44 [1.40; 1.47]	1.18 [1.15; 1.21]	<0.001
Allxiorytics	All	Female	1.36 [1.31; 1.41]	1.13 [1.09; 1.18]	-
		Male	1.51 [1.46; 1.56]	1.23 [1.18; 1.27]	_
	Natural	Both	1.45 [1.42; 1.49]	1.19 [1.16; 1.22]	<0.001
	ivaturai	Female	1.35 [1.30; 1.41]	1.13 [1.08; 1.18]	C0-001
		Male	1.56 [1.50; 1.61]	1.25 [1.20; 1.30]	-
	Unnatural	Both	1.30 [1.19; 1.42]	1.13 [1.03; 1.24]	0.080
	Official	Female	1.40 [1.19; 1.65]	1.21 [1.01; 1.44]	-
		Male	1.26 [1.13; 1.40]	1.10 [0.98; 1.23]	
Outratain and Han Markinskins	All	Both			0.033
Substance Use Medication	All	Female	1.29 [1.11; 1.50]	1.11 [0.95; 1.29]	0.033
			1.58 [1.25; 2.00]	1.33 [1.05; 1.68]	-
	Notural	Male	1.14 [0.94; 1.39]	0.99 [0.81; 1.21]	- 0.042
	Natural	Both	1.32 [1.12; 1.55]	1.13 [0.96; 1.32]	0.043
		Female	1.61 [1.27; 2.06]	1.36 [1.06; 1.73]	-
	l locatives!	Male	1.15 [0.93; 1.42]	0.99 [0.80; 1.23]	- 0.751
	Unnatural	Both	1.04 [0.62; 1.73]	0.94 [0.57; 1.56]	0.751
		Female	1.15 [0.37; 3.58]	0.98 [0.32; 3.06]	-
		Male	1.01 [0.57; 1.79]	0.93 [0.53; 1.64]	-

All models were adjusted for baseline age and time-updated calendar year. The models combining both sexes were adjusted for sex.